NEW YORK (GenomeWeb News) – Horizon Discovery announced today a research service agreement to deploy its X-MAN isogenic cell lines in support of Blueprint Medicine's "New Targets" discovery platform.
Blueprint is based in Cambridge, Mass., and develops highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal, Horizon will use its platform and expertise to screen certain Blueprint kinase inhibitor tool compounds on a panel of 26 X-MAN isogenic cell lines, in the process providing insights into "elucidating synthetic lethal interactions with approximately 100 kinase targets in various cancer subtypes."
Blueprint has developed a platform combining genomics expertise with a novel library of kinase inhibitors that allows the development of "potent, highly selective compounds to address clear genomic driver targets," Horizon said.
Financial and other terms were not disclosed.